T. Morgan
Hepatology · Annals of Internal Medicine · 2004–2013
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 28 citations into it
- Epidemiology — 16 citations into it
Whom T. Morgan trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- L. Seeff (in Hepatology)
Papers from T. Morgan's perspective
Ordered by how strongly the researchers T. Morgan trusts endorse each paper. Same corpus, a different order for every researcher.
- Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus (Journal of Experimental Medicine)
- Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection (Journal of Experimental Medicine)
- HCV-related fibrosis progression following liver transplantation: increase in recent years. (Journal of Hepatology)
- Hepatitis C virus infection. (New England Journal of Medicine)
- Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (Transfusion)
- Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome (Seminars in liver disease (Print))
- Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends (Seminars in liver disease (Print))
- The natural history of hepatitis C virus infection: host, viral, and environmental factors. (Journal of the American Medical Association (JAMA))
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (Nature Genetics)
- Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. (Gastroenterology)
Their papers
- A variant upstream of IFNL3 (IL28B) creating a novel interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus (2013) — 953 citations
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon (2008) — 600 citations
- The Natural History of Hepatitis C Virus (HCV) Infection (2006) — 896 citations
- Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) — 2,999 citations